ASH 2013: Dr. Neil Kay Discusses More about Clonal Evolutional and its Implications for Therapy

In the second part of my interview with Dr. Kay from Mayo that I just posted on my blog ( ), he talks about how a small resistant clone may become predominant and how long duration therapies may contribute to that risk.

It's worth wrapping our heads around because it has implications on how we should handle our disease and what research should be done.

Stay strong



You may also like...